B+
Bull case
25%
Probability
Target price
$66.00
+32.6% vs current
TECH
Bio-TechneDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$49.00
-1.5% vs current
B-
Bear case
25%
Probability
Target price
$36.00
-27.7% vs current
AI sentiment snapshot
Latest data as of 2026-05-19
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+49.3
Score
AI commentary
Post-print coverage looks mixed rather than euphoric: the official release highlighted solid pockets of growth but also a 2% revenue decline and continued biotech softness, and recent news flow noted both a strong trading day after the print and later underperformance versus peers. No analyst revision data were provided in the packet, so this remains a cautious monitoring view rather than a conviction upgrade.
RankAlpha Sentiment Codex - 2026-05-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06eventQ3 FY2026 print showed mixed execution but intact premium-growth nichesMedium impact
Bio-Techne reported Q3 FY2026 revenue down 2% to $311.4M and adjusted EPS down to $0.53, while GAAP EPS rose to $0.32 on margin improvement. Large pharma delivered its sixth straight quarter of double-digit growth, spatial biology grew mid-teens, and management said biotech funding has not yet translated into broad-based demand.
2026-05-29eventQuarterly cash dividend reinforces capital-return discipline [#8-K-2026-05-06]Medium impact
The board declared a $0.08/share dividend payable May 29, 2026 to holders of record May 18, 2026, which signals steady cash deployment but is unlikely to change the core growth debate.
2026-11-01catalystIf biotech funding and customer purchasing realign, mix could improve into a reacceleration phaseHigh impact
Management said it is seeing early indicators of a more constructive outlook as funding activity and customer purchasing begin to realign. If large-pharma demand, spatial biology, and GMP protein growth persist, Bio-Techne could earn a better long-term growth multiple.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-19 • Updated nightlySource: Internal modelMethodology